Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 47 of 47 entries
Sorted by: Best Match Show Resources per page
Trial watch: Chemotherapy with immunogenic cell death inducers.

Oncoimmunology

Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G.
PMID: 22720239
Oncoimmunology. 2012 Mar 01;1(2):179-188. doi: 10.4161/onci.1.2.19026.

The long-established notion that apoptosis would be immunologically silent, and hence it would go unnoticed by the immune system, if not tolerogenic, and hence it would actively suppress immune responses, has recently been revisited. In some instances, indeed, cancer...

Cite
Vacchelli E, Galluzzi L, Fridman WH, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1(2):179-188doi: 10.4161/onci.1.2.19026.
Vacchelli, E., Galluzzi, L., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., & Kroemer, G. (2012). Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology, 1(2), 179-188. https://doi.org/10.4161/onci.1.2.19026
Vacchelli, Erika, et al. "Trial watch: Chemotherapy with immunogenic cell death inducers." Oncoimmunology vol. 1,2 (2012): 179-188. doi: https://doi.org/10.4161/onci.1.2.19026
Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012 Mar 01;1(2):179-188. doi: 10.4161/onci.1.2.19026. PMID: 22720239; PMCID: PMC3376992.
Copy Download .nbib Format: NLM
Tumor microenvironment in NSCLC suppresses NK cells function.

Oncoimmunology

Cremer I, Fridman WH, Sautès-Fridman C.
PMID: 22720258
Oncoimmunology. 2012 Mar 01;1(2):244-246. doi: 10.4161/onci.1.2.18309.

NK cells, which contribute to tumor immunosurveillance, are present in the microenvironment of Non-Small-Cell Lung Carcinoma. However, they display strongly altered phenotype with decreased expression of NKp30, NKp80, DNAM-1, CD16 and ILT2, and impaired cytotoxic functions. The possible mechanisms...

Cite
Cremer I, Fridman WH, Sautès-Fridman C. Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology. 2012;1(2):244-246doi: 10.4161/onci.1.2.18309.
Cremer, I., Fridman, W. H., & Sautès-Fridman, C. (2012). Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology, 1(2), 244-246. https://doi.org/10.4161/onci.1.2.18309
Cremer, Isabelle, et al. "Tumor microenvironment in NSCLC suppresses NK cells function." Oncoimmunology vol. 1,2 (2012): 244-246. doi: https://doi.org/10.4161/onci.1.2.18309
Cremer I, Fridman WH, Sautès-Fridman C. Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology. 2012 Mar 01;1(2):244-246. doi: 10.4161/onci.1.2.18309. PMID: 22720258; PMCID: PMC3377004.
Copy Download .nbib Format: NLM
Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells.

Frontiers in immunology

Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I.
PMID: 23382731
Front Immunol. 2013 Feb 04;4:19. doi: 10.3389/fimmu.2013.00019. eCollection 2013.

Natural killer (NK) cells are able to recognize and kill tumor cells, however whether they contribute to tumor immunosurveillance is still debated. Our previous studies demonstrated the presence of NK cells in human lung tumors. Their comparison with NK...

Cite
Gillard-Bocquet M, Caer C, Cagnard N, et al. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol. 2013;4:19doi: 10.3389/fimmu.2013.00019.
Gillard-Bocquet, M., Caer, C., Cagnard, N., Crozet, L., Perez, M., Fridman, W. H., Sautès-Fridman, C., & Cremer, I. (2013). Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Frontiers in immunology, 419. https://doi.org/10.3389/fimmu.2013.00019
Gillard-Bocquet, Mélanie, et al. "Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells." Frontiers in immunology vol. 4 (2013): 19. doi: https://doi.org/10.3389/fimmu.2013.00019
Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol. 2013 Feb 04;4:19. doi: 10.3389/fimmu.2013.00019. eCollection 2013. PMID: 23382731; PMCID: PMC3563113.
Copy Download .nbib Format: NLM
Characteristics of tertiary lymphoid structures in primary cancers.

Oncoimmunology

Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.
PMID: 24498556
Oncoimmunology. 2013 Dec 01;2(12):e26836. doi: 10.4161/onci.26836. Epub 2013 Oct 22.

Tumors are sustained by complex networks of interactions between malignant cells, stromal cells and tumor-infiltrating immune cells. These networks differ from patient to patient in terms of nature, composition and organization as well as with regard to the precise...

Cite
Goc J, Fridman WH, Sautès-Fridman C, et al. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology. 2013;2(12):e26836doi: 10.4161/onci.26836.
Goc, J., Fridman, W. H., Sautès-Fridman, C., & Dieu-Nosjean, M. C. (2013). Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology, 2(12), e26836. https://doi.org/10.4161/onci.26836
Goc, Jérémy, et al. "Characteristics of tertiary lymphoid structures in primary cancers." Oncoimmunology vol. 2,12 (2013): e26836. doi: https://doi.org/10.4161/onci.26836
Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology. 2013 Dec 01;2(12):e26836. doi: 10.4161/onci.26836. Epub 2013 Oct 22. PMID: 24498556; PMCID: PMC3912008.
Copy Download .nbib Format: NLM
The immune microenvironment of human tumors: general significance and clinical impact.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J.
PMID: 23108700
Cancer Microenviron. 2013 Aug;6(2):117-22. doi: 10.1007/s12307-012-0124-9. Epub 2012 Oct 30.

Human cancers grow in a microenvironment of stromal, inflammatory and immunocompetent cells which is variable from tumor to tumor. The characterization of the immune contexture, i.e. the type, density and functional orientation of immunocompetent cells, the presence or absence...

Cite
Fridman WH, Dieu-Nosjean MC, Pagès F, et al. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron. 2012;6(2):117-22doi: 10.1007/s12307-012-0124-9.
Fridman, W. H., Dieu-Nosjean, M. C., Pagès, F., Cremer, I., Damotte, D., Sautès-Fridman, C., & Galon, J. (2013). The immune microenvironment of human tumors: general significance and clinical impact. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 6(2), 117-22. https://doi.org/10.1007/s12307-012-0124-9
Fridman, Wolf-Herman, et al. "The immune microenvironment of human tumors: general significance and clinical impact." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 6,2 (2013): 117-22. doi: https://doi.org/10.1007/s12307-012-0124-9
Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron. 2013 Aug;6(2):117-22. doi: 10.1007/s12307-012-0124-9. Epub 2012 Oct 30. PMID: 23108700; PMCID: PMC3717061.
Copy Download .nbib Format: NLM
Trial Watch: Toll-like receptor agonists for cancer therapy.

Oncoimmunology

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 24083080
Oncoimmunology. 2013 Aug 01;2(8):e25238. doi: 10.4161/onci.25238. Epub 2013 Jun 10.

Toll-like receptors (TLRs) have long been known for their ability to initiate innate immune responses upon exposure to conserved microbial components such as lipopolysaccharide (LPS) and double-stranded RNA. More recently, this family of pattern recognition receptors has been attributed...

Cite
Vacchelli E, Eggermont A, Sautès-Fridman C, et al. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013;2(8):e25238doi: 10.4161/onci.25238.
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013). Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology, 2(8), e25238. https://doi.org/10.4161/onci.25238
Vacchelli, Erika, et al. "Trial Watch: Toll-like receptor agonists for cancer therapy." Oncoimmunology vol. 2,8 (2013): e25238. doi: https://doi.org/10.4161/onci.25238
Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013 Aug 01;2(8):e25238. doi: 10.4161/onci.25238. Epub 2013 Jun 10. PMID: 24083080; PMCID: PMC3782517.
Copy Download .nbib Format: NLM
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.

Frontiers in immunology

Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC.
PMID: 27752258
Front Immunol. 2016 Oct 03;7:407. doi: 10.3389/fimmu.2016.00407. eCollection 2016.

Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that reflect lymphoid neogenesis occurring in tissues at sites of inflammation. They are detected in tumors where they orchestrate local and systemic anti-tumor responses. A correlation has been found between high...

Cite
Sautès-Fridman C, Lawand M, Giraldo NA, et al. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Front Immunol. 2016;7:407doi: 10.3389/fimmu.2016.00407.
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M. C. (2016). Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Frontiers in immunology, 7407. https://doi.org/10.3389/fimmu.2016.00407
Sautès-Fridman, Catherine, et al. "Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention." Frontiers in immunology vol. 7 (2016): 407. doi: https://doi.org/10.3389/fimmu.2016.00407
Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Front Immunol. 2016 Oct 03;7:407. doi: 10.3389/fimmu.2016.00407. eCollection 2016. PMID: 27752258; PMCID: PMC5046074.
Copy Download .nbib Format: NLM
Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Genome biology

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.
PMID: 27908289
Genome Biol. 2016 Dec 01;17(1):249. doi: 10.1186/s13059-016-1113-y.

No abstract available.

Cite
Becht E, Giraldo NA, Lacroix L, et al. Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):249doi: 10.1186/s13059-016-1113-y.
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., & de Reyniès, A. (2016). Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome biology, 17(1), 249. https://doi.org/10.1186/s13059-016-1113-y
Becht, Etienne, et al. "Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression." Genome biology vol. 17,1 (2016): 249. doi: https://doi.org/10.1186/s13059-016-1113-y
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A. Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016 Dec 01;17(1):249. doi: 10.1186/s13059-016-1113-y. PMID: 27908289; PMCID: PMC5134277.
Copy Download .nbib Format: NLM
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade.

Cancer immunology research

Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT.
PMID: 34039652
Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26.

The complement system is a powerful and druggable innate immune component of the tumor microenvironment. Nevertheless, it is challenging to elucidate the exact mechanisms by which complement affects tumor growth. In this study, we examined the processes by which...

Cite
Daugan MV, Revel M, Thouenon R, et al. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021;9(8):909-925doi: 10.1158/2326-6066.CIR-20-0787.
Daugan, M. V., Revel, M., Thouenon, R., Dragon-Durey, M. A., Robe-Rybkine, T., Torset, C., Merle, N. S., Noé, R., Verkarre, V., Oudard, S. M., Mejean, A., Validire, P., Cathelineau, X., Sanchez-Salas, R., Pickering, M. C., Cremer, I., Mansuet-Lupo, A., Alifano, M., Sautès-Fridman, C., Damotte, D., Fridman, W. H., & Roumenina, L. T. (2021). Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer immunology research, 9(8), 909-925. https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan, Marie V, et al. "Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade." Cancer immunology research vol. 9,8 (2021): 909-925. doi: https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26. PMID: 34039652.
Copy Download .nbib Format: NLM
The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.

Frontiers in immunology

Fridman WH, Teillaud JL, Sautès-Fridman C, Pagès F, Galon J, Zucman-Rossi J, Tartour E, Zitvogel L, Kroemer G.
PMID: 22566855
Front Immunol. 2011 Dec 01;2:66. doi: 10.3389/fimmu.2011.00066. eCollection 2011.

No abstract available.

Cite
Fridman WH, Teillaud JL, Sautès-Fridman C, et al. The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol. 2011;2:66doi: 10.3389/fimmu.2011.00066.
Fridman, W. H., Teillaud, J. L., Sautès-Fridman, C., Pagès, F., Galon, J., Zucman-Rossi, J., Tartour, E., Zitvogel, L., & Kroemer, G. (2011). The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in immunology, 266. https://doi.org/10.3389/fimmu.2011.00066
Fridman, Wolf H, et al. "The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response." Frontiers in immunology vol. 2 (2011): 66. doi: https://doi.org/10.3389/fimmu.2011.00066
Fridman WH, Teillaud JL, Sautès-Fridman C, Pagès F, Galon J, Zucman-Rossi J, Tartour E, Zitvogel L, Kroemer G. The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol. 2011 Dec 01;2:66. doi: 10.3389/fimmu.2011.00066. eCollection 2011. PMID: 22566855; PMCID: PMC3341952.
Copy Download .nbib Format: NLM
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research

Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S.
PMID: 34407968
Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18.

PURPOSE: A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types,...

Cite
Terry S, Dalban C, Rioux-Leclercq N, et al. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021;27(24):6749-6760doi: 10.1158/1078-0432.CCR-21-0972.
Terry, S., Dalban, C., Rioux-Leclercq, N., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., Lacroix, G., Lorens, J. B., Gausdal, G., Fridman, W. H., Mami-Chouaib, F., Chaput, N., Beuselinck, B., Chabaud, S., Barros-Monteiro, J., Vano, Y., Escudier, B., Sautès-Fridman, C., Albiges, L., & Chouaib, S. (2021). Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6749-6760. https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry, Stéphane, et al. "Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6749-6760. doi: https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18. PMID: 34407968.
Copy Download .nbib Format: NLM
Showing 37 to 47 of 47 entries